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Technical Note
Introduction
Biological drugs such as therapeutic antibodies are in the pro-
cess of replacing chemical compounds as the major class of 
future medicines. Therapeutic antibodies are often character-
ized by complex modes of action, such as inhibition of cell 
proliferation, induction of apoptosis, and targeted immune 
recruitment. Moreover, antibody drug conjugates (ADCs) 
that combine chemotherapeutic cytotoxicity with antibody-
mediated tumor specificity even increase the diversity of 
potential modes of action.1 Thus, the functional characteriza-
tion during early drug development requires sensitive cell-
based high-throughput assays that address this complexity 
and measure multiple cellular parameters.2 One of the major 
modes of action of therapeutic antibodies is based on inhibi-
tion of target cell growth by, for example, blocking growth 
signaling pathways in cancer cells.3 For assessing the antip-
roliferative potency of such candidates, several methods have 
been described.4 A simple approach to quantify the number 
of cells that survive treatment consists of automated cell 
counting.5 However, a significant proportion of remaining 
cells is likely to have entered apoptosis or cell cycle arrest, 
leading to an overestimation of the proliferating cell 
population. A more precise approximation of proliferation 
can be achieved by detecting metabolic activity in viable 
cells and thus excluding apoptotic cells. Compounds such as 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) are converted to a colored product by NAD(P)H- 
dependent cellular oxidoreductases, providing a quantifiable 
measure for metabolic activity.6 An alternative approach to 
assess viability is the detection of intracellular adenosine tri-
phosphate (ATP), which is maintained only at high levels in 
metabolically active cells and declines rapidly upon cell 
death or apoptosis. The release of intracellular ATP and its 
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Abstract
Monoclonal antibodies (mAbs) have become a central class of therapeutic agents in particular as antiproliferative compounds. 
Their often complex modes of action require sensitive assays during early, functional characterization. Current cell-based 
proliferation assays often detect metabolites that are indicative of metabolic activity but do not directly account for cell 
proliferation. Measuring DNA replication by incorporation of base analogues such as 5-bromo-2′-deoxyuridine (BrdU) 
fills this analytical gap but was previously restricted to bulk effect characterization in enzyme-linked immunosorbent assay 
formats. Here, we describe a cell-based assay format for the characterization of antiproliferative mAbs regarding potency 
and mode of action in a single experiment. The assay makes use of single cell–based high-content-analysis (HCA) for 
the reliable quantification of replicating cells and DNA content via 5-ethynyl-2′-deoxyuridine (EdU) and 4′,6-diamidino-
2-phenylindole (DAPI), respectively, as sensitive measures of antiproliferative mAb activity. We used trastuzumab, an 
antiproliferative therapeutic antibody interfering with HER2 cell surface receptor-mediated growth signal transduction, 
and HER2-overexpressing cell lines BT474 and SKBR3 to demonstrate up to 10-fold signal-to-background (S/B) ratios 
for treated versus untreated cells and a shift in cell cycle profiles indicating antibody-induced cell cycle arrest. The assay 
is simple, cost-effective, and sensitive, providing a cell-based format for preclinical characterization of therapeutic mAbs.
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detection via ATP-dependent luciferase activity is widely 
used in proliferation assays.7
However, cells that have undergone cell cycle arrest are still 
metabolically active and consequently not distinguishable 
from proliferating cells by above-described assays. A major 
characteristic of proliferating cells is the replication of DNA 
during S phase. Thus, the incorporation of nucleotide ana-
logues such as 5-bromo-2′-deoxyuridine (BrdU) into chromo-
somal DNA during replication allows for the distinction 
between proliferating and arrested cells. BrdU can be detected 
by antibodies and thus may be implemented with highly sensi-
tive enzyme-linked immunosorbent assay (ELISA)–based 
multiwell assays.8 It has been shown that a wider separation 
between signals from treated and untreated samples (signal-to-
background [S/B] ratio) can be achieved with BrdU incorpora-
tion compared with assays detecting metabolic activity.9 
5-Ethynyl-2′-deoxyuridine (EdU), an alternative nucleotide 
analogue, enables a simpler, milder, and more efficient detec-
tion via copper-catalyzed azide alkyne cycloaddition (CuAAC) 
of fluorescent dyes, such as 6-FAM–azide. The use of EdU 
coupled to fluorescent dyes simplifies the assay procedure and 
in addition improves compatibility with other nuclear stains 
such as 4′,6-diamidino-2-phenylindole (DAPI), thus represent-
ing the method of choice for sensitive microscopy-based 
detection of proliferation.
Accurate distinction between proliferating and nonpro-
liferating cells improves the sensitivity of an antiprolifera-
tive potency assay (Fig. 1). Changing the mode of signal 
detection, on one hand, can further improve sensitivity but 
also provide additional information about the antiprolifera-
tive effect. Plate reader–based readouts are commonly used 
in screening experiments to validate lead candidates and 
produce statistically relevant data. Commonly used colori-
metric multiwell proliferation assays are restricted to single- 
course parameters such as mean metabolic activity per well. 
To better understand the mode of action underlying an 
antiproliferative effect, cellular or subcellular information 
on signal localization and intensity may prove useful, which 
is usually not accessible with plate reader systems. 
Fluorescence microscopy is the method of choice to gain 
information about single cells with a variety of microscopic 
high-content screening (HCS) platforms developed in 
recent years that allow for automated image acquisition and 
analysis in a high-throughput manner.10
In the present study, we describe a simple and sensitive 
microscopic high-content assay for the quantification and 
characterization of the antiproliferative potency of thera-
peutic antibodies. The quantification of replicating cells, 
via EdU incorporation, as a measure for proliferation allows 
for most sensitive distinction between proliferating and 
nonproliferating cells. In addition to quantifying the antip-
roliferative potency of a monoclonal antibody (mAb), the 
mode of action can be investigated in the course of the same 
experiment. For example, potential induction of cell cycle 
arrest can be studied by cell cycle profiling based on nuclear 
DNA content quantification.
Materials and Methods
Cell Lines and Cell Culture
Antibodies were produced in FreeStyle HEK 293-F cells 
(Thermo Fisher Scientific, Waltham, MA, USA) cultured in 
FreeStyle 293 Expression Medium and maintained at cell 
densities from 3 × 105 to 3 × 106 cells/mL in a shaker flask 
at 37 °C, 5% CO2, shaking at 120 rpm.
HER2 overexpression cell lines BT474 (ATCC HTB20) 
and SKBR3 (ATCC HTB30) and a control cell line with 
neglectable HER2 expression levels (1000-fold less than 
SKBR3), MDA-MB-468 (ATCC HTB-132), were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM)/F12 + 
Gibco Glutamax-I (Thermo Fisher Scientific, Waltham, 
Figure 1. Addressing proliferation at different layers. Antiproliferative antibodies interfere with a cell’s ability to replicate. Directly, 
detecting replicating cells (green) allows for the largest separation between maximal and minimal number of affected cells. Indirectly, 
restrained DNA replication also reduces the amount of metabolically active cells and the total number of cells remaining after 
treatment. However, the detection of metabolically active cells (magenta) includes arrested cells, resulting in an overestimation of 
proliferating cells. This effect is even more drastic when further generalizing the detection to all remaining cells (orange), which also 
includes apoptotic cells.
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MA, USA) supplemented with 10% fetal calf serum (FCS) 
at 37 °C, 5% CO2.
Protein Expression and Purification
Trastuzumab was expressed in FreeStyle HEK 293-F cells as 
described previously from the pVITRO1-trastuzumab-IgG1/κ 
vector (Addgene plasmid 61883; Addgene, Cambridge, MA, 
USA).11
Antibody purification from cleared and sterile filtered cell 
culture supernatants was performed with an Äkta purifier 
system equipped with a 1-mL HiTrap Protein A HP column 
(GE Healthcare, Piscataway, NJ). The system was operated 
with a constant flow rate of 1 mL/min. After sample applica-
tion, the column was washed with 10 column volumes (CVs) 
of wash buffer (20 mM phosphate buffer, 150 mM NaCl, pH 
7.3). Bound antibody was eluted with a one-step pH decrease 
to 3.0 (10 mM Na-citrate buffer, pH 3.0). Eluted fractions of 
size 0.2 mL or 0.5 mL were collected followed by immediate 
neutralization of the pH with one-third volume 1 M Tris HCl, 
pH 8.0. Peak fractions were pooled and concentrated using 
an Amicon Ultra 4-mL Centrifugal Filter NMWL 10 kDa 
(Merck Millipore, Billerica, MA, USA) and stored at 4 °C or 
snap frozen in liquid nitrogen and transferred to −80 °C for 
long-term storage.
Antibody Treatment, EdU Incorporation, and 
Nuclear Staining
In total, 1 × 104 cells were seeded in each well of a 96-well 
optical cell culture plate supplemented with 100 µL culture 
media. To ensure proper attachment, cells were incubated for 
4 h prior to addition of antibody. The 1:3 serial dilutions of 
trastuzumab in culture media were performed at threefold the 
desired final concentration, ranging from 50 nM to 0 nM. 
Then, 50 µL of each dilution was added in triplicates to indi-
vidual wells. Cells were incubated with antibody for 4 days 
followed by the addition of EdU to a final concentration of 10 
µM. To guarantee labeling of all proliferating cells, EdU 
treatment was done for 20 h followed by fixation of cells in 
phosphate-buffered saline (PBS) + 4% paraformaldehyde 
(PFA), permeabilization in PBS + 0.5% Triton X-100, and 
blocking of the well surface with PBT (PBS, 2% BSA, and 
0.02% Tween 20). EdU was labeled via CuAAC by the addi-
tion of 30 µL of staining reagent (4 mM CuSO4, 20 µM 
6-FAM–azide, 50 µM Na-ascorbate in 100 mM Tris/HCl, pH 
7.0) per well and incubated for 30 min at room temperature. 
Remaining unconjugated dye was removed by washing three 
times with 100 µL PBST (PBS + 0.02% Tween 20). Then, 
100 ng/mL DAPI in PBST was added for 10 min at room 
temperature to counterstain nuclear DNA, followed by three 
washing steps with PBST and one additional wash with 
ddH2O.
Image Acquisition and Data Analysis
Images were acquired with an Operetta High-Content 
Imaging system (PerkinElmer, Waltham, MA, USA) 
equipped with a 40× high NA objective. The 380/40-nm 
excitation and 410- to 480-nm emission filters were used to 
image DAPI, and the 475/30-nm excitation and 500- to 
550-nm emission filters were used to image 6-FAM–EdU.
DAPI images were used to segment and count the total 
number of nuclei for each well, representing the total cell 
count. Each antibody concentration was tested in technical 
triplicates. Total cell counts of triplicates were averaged and 
normalized to the cell count of an untreated control 
(c(trastuzumab) = 0). Averaged and normalized cell counts 
were plotted against log10-transformed antibody concentra-
tions. Fitting a nonlinear four-parametric model equation 
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culating total DAPI intensities of segmented nuclei. 
Absolute DAPI intensities per nucleus were subgrouped by 
binning and plotted as a probability histogram to analyze 
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modeling S phase, were fitted to the DAPI intensity proba-
bility densities px and histogram bin centers x to model the 
DNA content distribution throughout the cell cycle. The 
function was fitted by globally minimizing the squared 
error via simulated annealing using the GenSA package in 
R. By integrating over the respective term of the derived fit 
equation representing the G1, S, or G2/M phase, the relative 
proportion of each phase of the whole cell population was 
calculated—for example,
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Based on 6-FAM–EdU signal, nuclei were classified as pro-
liferating or nonproliferating. Data averaging, normaliza-
tion, and curve fitting were done in a similar manner as 
described above for total cell counts.
All image processing was performed with the Harmony 
software (PerkinElmer); data analysis and curve fitting were 
done in MATLAB and R (2016, https://www.R-project.org). 
The R script used for the estimation of cell cycle distribu-
tions from DAPI intensity distributions is available at https://
github.com/hoerldavid/CellCycleFit.
Results and Discussion
In the field of biologics, therapeutic antibodies have 
emerged as an especially promising drug format over the 
past years.2 A role model for this class of drugs is trastu-
zumab, which binds the extracellular domain of the HER2 
cell surface receptor. In a subset of breast cancers, the 
growth factor receptor HER2 is overexpressed and medi-
ates increased proliferation.12 Trastuzumab counteracts this 
accelerated growth by reducing HER2-mediated signaling 
and therefore acting as an antiproliferative drug on HER2-
overexpressing cells.13 To assess the antiproliferative potency 
of a therapeutic antibody, cells are subjected to a range of 
antibody concentrations. Higher antibody concentrations 
are expected to lead to lower numbers of viable cells and 
an even more pronounced decrease in proliferating cells 
(Fig. 1).
In the described assay, HER2-overexpressing cells (BT474 
and SKBR3) and control cells (MDA-MB-468) were supple-
mented with EdU after 4 days of trastuzumab treatment. The 
proliferating fraction of the cell population incorporates EdU 
molecules into newly synthesized DNA during S phase. 
Surviving cells are stained with DAPI, whereas the incorpo-
rated EdU is labeled by CuAAC-mediated coupling of the 
fluorescent dye 6-FAM–azide. Imaging of stained cells on an 
Operetta system facilitates the detection and segmentation of 
nuclei, DNA content analysis using the DAPI signal, and 
definition of the proliferation status according to the EdU sig-
nal. Testing multiple antibodies over a range of concentra-
tions is conveniently done in a multiwell tissue culture plate, 
which is compatible with the Operetta HCS imaging system. 
With this setup, an inhibition curve with 10 data points as 
technical triplicates can easily be generated for two individ-
ual antibodies in a 96-well format. Quantification of counted 
nuclei and detected proliferating cells can readily be done 
with the built-in software package of the Operetta system 
(Harmony), whereas statistical analysis and curve fitting are 
conveniently handled with respective MATLAB toolboxes. 
Besides the quantification of total cell counts and proliferat-
ing cells, the relative intensities of the DAPI and/or EdU sig-
nal per nucleus provide additional information with regard to 
cell cycle phase distributions.
Cell Survival and Cell Cycle Progression
Treatment of HER2-overexpressing cell lines with trastu-
zumab leads to a reduction in cell growth, but BT474 cells 
have been reported to be more susceptible than SKBR3 
cells.14 After 4 days of treatment, fluorescence microscopy 
of DAPI-stained nuclei indicates a clear reduction in cells 
with increasing concentrations of trastuzumab for BT474 
(Fig. 2A) as well as SKBR3 cells. Next, we performed 
high-content image analysis by nuclei segmentation and 
subsequent quantification of surviving cells as a function of 
antibody concentration. By fitting a four-parametric nonlin-
ear model to the obtained data points, we calculated inhibi-
tion curves. These fits revealed a decrease in total cell 
number with increasing antibody concentration and S/B 
ratios lower than 3 for BT474 (Fig. 2B) and SKBR3 (Fig. 
2C). The maximal induction of cell death is 64% with a 
concentration of half maximal inhibition (IC50) of 1.8 nM 
for BT474 cells and 65% with an IC50 value of 1.9 nM for 
SKBR3 cells. The low S/B values can be explained by the 
specific mode of action mediated by trastuzumab, deceler-
ating cell proliferation rather than actively promoting cell 
death.14 Therefore, cells that have already passed G1 phase 
will further progress in cell cycle. With BT474 and SKBR3 
cells exhibiting long doubling times (2–3 days), S/B ratios 
greater than 4 (two doublings) are not to be expected in the 
time course of the assay, which holds also true for other 
assays merely detecting survival or viability.9 Moreover, a 
very low Hill slope could be observed for SKBR3 cells 
compared with BT474, which is linked to the lower suscep-
tibility of SKBR3 to trastuzumab.9,14 Consistently, an 
unsusceptible cell line (MDA-MB-468) showed no differ-
ence in the number of viable cells between treated and 
untreated conditions (Fig. 2B,C). These results indicate that 
exclusively measuring cell survival is limiting the S/B ratio 
of proliferation assays, since arrested cells, which are still 
metabolically active, cannot be distinguished from prolifer-
ating cells.
High-content image analysis of DAPI-stained nuclei allows 
not only segmentation and quantification of nuclei but also 
the measurement of relative nuclear DNA contents. Since the 
amount of chromosomal DNA doubles through S phase from 
G1 to G2 phase, the absolute DAPI signal per nucleus can be 
used to analyze changes in cell cycle distributions. In this 
line, we generated frequency histograms of the absolute 
DAPI intensity per nucleus (Fig. 3A and Suppl. Fig. S1). 
Fitting a three-term model function to the data allowed us to 
determine the proportion of cells within each cell cycle phase 
(Fig. 3B). SKBR3 cells exhibited a clear change in cell cycle 
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profiles upon trastuzumab treatment. The quantification of 
these data shows a decrease in the G2 phase population with 
increasing antibody concentration, which suggests an arrest 
in either G1 or S phase. This is consistent with the proposed 
G1 arrest induced by trastuzumab.15
Cell cycle profiles are an additional readout of the 
described assay and provide supplementary information 
about the mode of action of an antiproliferative antibody. 
Investigation of potency and mode of action in a single exper-
iment was facilitated by increasing resolution to the single-
cell level combined with high-throughput sample and data 
handling implemented in HCS systems. Cell cycle analysis of 
the less susceptible SKBR3 cell line showed that we are able 
to analyze an antibody’s mode of action even if the overall 
Figure 2. Quantification of antiproliferative potency by counting nuclei of surviving cells. 4′,6-Diamidino-2-phenylindole (DAPI)–
stained nuclei were imaged with an Operetta high-content screening (HCS) system. Representative images of BT474 cells for four 
different antibody concentrations are shown in (A). Scale bar represents 100 µm. The observed decrease in surviving cells was 
quantified from technical triplicates for nine individual antibody concentrations (0.008–50 nM) and an untreated control. Averaged 
triplicates normalized to untreated control were plotted against log10-transformed trastuzumab concentrations for BT474 (B) and 
SKBR3 (C) and fitted to a four-parametric inhibition curve model equation (solid lines). Proliferation of a negative control cell line, 
MDA-MB-468, was unaffected by trastuzumab treatment (dashed line). The maximal difference in the number of surviving cells was 
2.7-fold for BT474 as well as for SKBR3 cells.
Figure 3. Shift in cell cycle distribution of trastuzumab-treated SKBR3 cells. Nuclear 4′,6-diamidino-2-phenylindole (DAPI) intensities 
were analyzed to categorize cells into cell cycle phases according to their relative DNA content. Probability density histograms of 
DAPI intensities were used to fit a model equation to the observed distribution. An exemplary histogram for c(trastuzumab) = 16 nM 
is given in (A) with the fitted curve in cyan and respective cell cycle phase terms in red (G1), blue (S), and green (G2/M). Integration 
over the individual terms yields the proportion of cells in each cell cycle phase treated with different trastuzumab concentrations (B). 
High concentrations of trastuzumab lead to a reduction in the G2/M phase proportion, indicating cell cycle arrest.
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antiproliferative effect is weak. Nevertheless, it is also 
desirable to detect this weak proliferation inhibition with 
greater resolution. To address this need, we chose EdU 
incorporation for sensitive detection of proliferating cells.
Increased Assay Sensitivity via Quantification of 
EdU Incorporating Cells
Since DNA replication is a major characteristic of prolifera-
tion, we decided to use EdU incorporation as a marker for 
proliferating cells. Labeling EdU with a fluorescent dye 
allowed the distinction between proliferating and nonprolif-
erating cells by fluorescence microscopy. Automated quan-
tification of EdU-positive cells increased the S/B ratio to 10 
for treated versus untreated BT474 cells (Fig. 4B). A con-
centration of half maximal inhibition (IC50) of 4.9 nM was 
obtained from the fitted inhibition curve, whereas the 
maximal induction of proliferation inhibition was 90%. For 
SKBR3 cells, we observed a maximal induction of prolif-
eration inhibition of 64% and IC50 of 3.9 nM. To ensure that 
the detected inhibition of proliferation was due to trastuzumab-
mediated effects, we subjected a control cell line, 
MDA-MB-468, to the same treatment. As expected, we 
could not observe any difference in the proliferating frac-
tion upon addition of trastuzumab (Fig. 4B,C). We could 
show that EdU incorporation-based detection of proliferat-
ing cells by microscopy greatly increases the S/B ratio com-
pared with detecting surviving cells and improves the 
inhibition curve parameters such as Hill slope in the case of 
SKBR3 (Fig. 4C). A 10-fold change in proliferation has 
recently also been demonstrated with a DELFIA-BrdU–
based assay.9 However, the assay described in the present 
article uses the more sensitive and mild EdU staining 
method, provides the possibility for multiplexed readout of 
Figure 4. Improving assay sensitivity by detecting proliferating cells via 5-ethynyl-2′-deoxyuridine (EdU) incorporation. EdU, 
incorporated into chromosomal DNA during replication, was labeled by copper-catalyzed azide alkyne cycloaddition (CuAAC) with 
6-FAM and imaged with an Operetta high-content screening (HCS) system. Representative images of BT474 cells are shown in (A). 
Scale bar represents 100 µm. Segmented nuclei from Figure 2A were classified as proliferating (green) or nonproliferating (red) 
based on EdU signal presence. It is clearly visible that only a small fraction of all surviving cells is still proliferating at high antibody 
concentrations. Results of quantification of proliferating cells and data fitting similar to data in Figure 2 are shown for BT474 cells 
(B) and SKBR3 cells (C). The signal to background (S/B) ratio could be greatly improved for BT474 cells from 2.7 to 10 compared 
with surviving cell quantification (Fig. 2). SKBR3 cells exhibit an S/B ratio of 2.8, which is comparable to the value derived from 
4′,6-diamidino-2-phenylindole (DAPI)–based quantification of surviving cells (2.7).
Stengl et al. 315
various parameters, and increases the assay resolution by 
the detection of single cells instead of averaging over a bulk 
population.
In summary, we could show that EdU-based labeling of 
proliferating cells with subsequent automated imaging and 
analysis combined with DAPI-based cell cycle profiling is 
a simple and sensitive way for parallel investigation of anti-
proliferative potency and mode of action of therapeutic 
antibodies.
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